Amantadine as a drug to mitigate the effects of COVID-19
- 25 April 2020
- journal article
- research article
- Published by Elsevier BV in Medical Hypotheses
- Vol. 140, 109755
- https://doi.org/10.1016/j.mehy.2020.109755
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trialInternational Journal of Antimicrobial Agents, 2020
- Inhibitory Mechanisms of DHA/CQ on pH and Iron Homeostasis of Erythrocytic Stage Growth of Plasmodium falciparumMolecules, 2019
- Inhibitors of the M2 Proton Channel Engage and Disrupt Transmembrane Networks of Hydrogen-Bonded WatersJournal of the American Chemical Society, 2018
- Structural model of the SARS coronavirus E channel in LMPG micellesBiochimica et Biophysica Acta (BBA) - Biomembranes, 2018
- The PDZ-Binding Motif of Severe Acute Respiratory Syndrome Coronavirus Envelope Protein Is a Determinant of Viral PathogenesisPLoS Pathogens, 2014
- Conductance and amantadine binding of a pore formed by a lysine‐flanked transmembrane domain of SARS coronavirus envelope proteinProtein Science, 2007
- PatchDock and SymmDock: servers for rigid and symmetric dockingNucleic Acids Research, 2005
- Ion channel activity of influenza A virus M2 protein: characterization of the amantadine blockJournal of Virology, 1993
- Plasmodium falciparum: effects of amantadine, an antiviral, on chloroquine-resistant and -sensitive parasites in vitro and its influence on chloroquine activityBiochemical Pharmacology, 1993
- A simple method for displaying the hydropathic character of a proteinJournal of Molecular Biology, 1982